Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002574 · ClinicalTrials.gov registry record · Phase 2
Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00002574: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00002574 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002574, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.
Interventions
- BIOLOGICAL recombinant interferon alfa
- DRUG omacetaxine mepesuccinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 1994-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002574
The ClinicalTrials.gov registry entry for NCT00002574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00002574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002574 about?
NCT00002574 is a clinical study titled "Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia". Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of ca...
What is the current status of trial NCT00002574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 1994-09.
What interventions are being tested in trial NCT00002574?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), omacetaxine mepesuccinate (DRUG).
Who is sponsoring clinical trial NCT00002574?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.